logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Efgartigimod alfa for treating generalised myasthenia gravis

< Back

Efgartigimod alfa for treating generalised myasthenia gravis

Drugs

September 2021


Efgartigimod alfa is currently in clinical development for the treatment of adults with generalised myasthenia gravis (gMG). gMG is a long-term autoimmune disorder that leads to muscle weakness and tiredness, and which can be seriously debilitating and life-threatening. Currently there are no medicinal products recommended by NICE specifically for the treatment of gMG, and medicines that are used are mostly unlicensed, can take a long time to work and result in side-effects.
Efgartigimod alfa is a modified human antibody (a protein produced by the immune system) fragment that is administered by intravenous (IV) infusion. In patients with myasthenia gravis, the body produces antibodies against the acetylcholine receptors. This medicine works by blocking a protein called FcRn, which attaches to these antibodies and protects them from degradation. Blocking FcRn leads to the degradation of the antibodies that damage the acetylcholine receptors; this is expected to restore the normal contraction of the muscles. If licensed, efgartigimod alfa will offer a treatment option for gMG and reduce the treatment burden for these patients.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Get Alerts